Cellectis Stock Forecast, Price & News

+0.59 (+4.56 %)
(As of 08/2/2021 01:29 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume10,038 shs
Average Volume322,402 shs
Market Capitalization$615.54 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CLLS News and Ratings via Email

Sign-up to receive the latest news and ratings for Cellectis and its competitors with MarketBeat's FREE daily newsletter.

Cellectis logo

About Cellectis

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat. It has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. The company was founded in 1999 and is headquartered in Paris, France.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.83 out of 5 stars

Medical Sector

741st out of 2,221 stocks

Biological Products, Except Diagnostic Industry

109th out of 214 stocks

Analyst Opinion: 3.4Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Cellectis (NASDAQ:CLLS) Frequently Asked Questions

Is Cellectis a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cellectis in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Cellectis stock.
View analyst ratings for Cellectis
or view top-rated stocks.

What stocks does MarketBeat like better than Cellectis?

Wall Street analysts have given Cellectis a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cellectis wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Cellectis?

Cellectis saw a drop in short interest in the month of June. As of June 15th, there was short interest totaling 1,190,000 shares, a drop of 21.7% from the May 31st total of 1,520,000 shares. Based on an average daily trading volume, of 267,100 shares, the short-interest ratio is presently 4.5 days. Currently, 2.6% of the company's shares are sold short.
View Cellectis' Short Interest

When is Cellectis' next earnings date?

Cellectis is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Cellectis

How can I listen to Cellectis' earnings call?

Cellectis will be holding an earnings conference call on Friday, August 6th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 877-660-6853 with passcode "13721394".

How were Cellectis' earnings last quarter?

Cellectis S.A. (NASDAQ:CLLS) announced its quarterly earnings data on Thursday, May, 6th. The biotechnology company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.82) by $0.54. The biotechnology company earned $27.97 million during the quarter, compared to analyst estimates of $8.14 million. Cellectis had a negative net margin of 200.21% and a negative trailing twelve-month return on equity of 36.24%.
View Cellectis' earnings history

How has Cellectis' stock price been impacted by Coronavirus (COVID-19)?

Cellectis' stock was trading at $11.43 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CLLS shares have increased by 18.9% and is now trading at $13.59.
View which stocks have been most impacted by COVID-19

What price target have analysts set for CLLS?

5 Wall Street analysts have issued twelve-month target prices for Cellectis' shares. Their forecasts range from $32.00 to $39.00. On average, they anticipate Cellectis' share price to reach $34.67 in the next twelve months. This suggests a possible upside of 155.1% from the stock's current price.
View analysts' price targets for Cellectis
or view top-rated stocks among Wall Street analysts.

Who are Cellectis' key executives?

Cellectis' management team includes the following people:
  • Dr. Andre Choulika, Co-Founder, CEO & Director (Age 56, Pay $1.15M)
  • Dr. David J. D. Sourdive, Co-Founder, Exec. VP of Strategic Initiatives & Director (Age 54, Pay $476.63k)
  • Mr. Eric Dutang, Chief Financial Officer (Age 47)
  • Mr. Jean Charles Epinat, Chief Technological Officer
  • Ms. Marie-Bleuenn Terrier, Gen. Counsel & Sec. of the Board of Directors (Age 39)
  • Ms. Jennifer Moore, Sr. VP of PR
  • Ms. Kyung Nam-Wortman, Exec. VP & Chief HR Officer (Age 51)
  • Dr. Philippe Duchateau Ph.D., Chief Scientific Officer (Age 58)
  • Mr. Stephan Reynier, Chief Regulatory & Pharmaceutical Compliance Officer (Age 52)
  • Simon Harnest, Sr. VP of Corp. Strategy & Fin.

What is André Choulika's approval rating as Cellectis' CEO?

4 employees have rated Cellectis CEO André Choulika on André Choulika has an approval rating of 100% among Cellectis' employees. This puts André Choulika in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Cellectis' key competitors?

What other stocks do shareholders of Cellectis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectis investors own include Gilead Sciences (gild), Calyxt (CLXT), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), Intel (INTC) and Sorrento Therapeutics (SRNE).

When did Cellectis IPO?

(CLLS) raised $129 million in an IPO on Wednesday, March 25th 2015. The company issued 3,500,000 shares at a price of $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray served as the underwriters for the IPO and Oppenheimer was co-manager.

What is Cellectis' stock symbol?

Cellectis trades on the NASDAQ under the ticker symbol "CLLS."

Who are Cellectis' major shareholders?

Cellectis' stock is owned by a number of institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (2.27%), Sumitomo Mitsui Trust Holdings Inc. (1.75%) and Exchange Traded Concepts LLC (0.49%).

Which major investors are selling Cellectis stock?

CLLS stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc..

Which major investors are buying Cellectis stock?

CLLS stock was bought by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., and Exchange Traded Concepts LLC.

How do I buy shares of Cellectis?

Shares of CLLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cellectis' stock price today?

One share of CLLS stock can currently be purchased for approximately $13.59.

How much money does Cellectis make?

Cellectis has a market capitalization of $617.81 million and generates $82.46 million in revenue each year. The biotechnology company earns $-81,070,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis.

How many employees does Cellectis have?

Cellectis employs 272 workers across the globe.

What is Cellectis' official website?

The official website for Cellectis is

Where are Cellectis' headquarters?

Cellectis is headquartered at 8 RUE DE LA CROIX JARRY, PARIS I0, 75013.

How can I contact Cellectis?

Cellectis' mailing address is 8 RUE DE LA CROIX JARRY, PARIS I0, 75013. The biotechnology company can be reached via phone at 33-1-81-69-16-00 or via email at [email protected]

This page was last updated on 8/2/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.